Mineralys Therapeutics Inc (NASDAQ: MLYS) is 31.19% higher on its value in year-to-date trading and has touched a low of $8.24 and a high of $18.38 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The MLYS stock was last observed hovering at around $16.78 in the last trading session, with the day’s loss setting it -0.63%.
Currently trading at $16.15, the stock is 20.41% and 43.40% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.32 million and changing -3.75% at the moment leaves the stock 32.35% off its SMA200. MLYS registered 25.78% gain for a year compared to 6-month loss of 41.05%. The firm has a 50-day simple moving average (SMA 50) of $11.1266 and a 200-day simple moving average (SMA200) of $12.18895.
The stock witnessed a 84.36% gain in the last 1 month and extending the period to 3 months gives it a 30.88%, and is -3.58% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.10% over the week and 10.40% over the month.
Mineralys Therapeutics Inc (MLYS) has around 51 employees, a market worth around $1.01B and $0.00M in sales. Distance from 52-week low is 95.97% and -12.13% from its 52-week high. The company has generated returns on investments over the last 12 months (-92.97%).
The EPS is expected to shrink by -6.33% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
157.0 institutions hold shares in Mineralys Therapeutics Inc (MLYS), with institutional investors hold 88.85% of the company’s shares. The shares outstanding are 49.82M, and float is at 36.97M with Short Float at 6.00%. Institutions hold 87.07% of the Float.
The top institutional shareholder in the company is CATALYS PACIFIC, LLC with over 9.19 million shares valued at $107.58 million. The investor’s holdings represent 18.629 of the MLYS Shares outstanding. As of 2024-06-30, the second largest holder is SAMSARA BIOCAPITAL, LLC with 5.07 million shares valued at $59.38 million to account for 10.2822 of the shares outstanding. The other top investors are RA CAPITAL MANAGEMENT, L.P. which holds 4.85 million shares representing 9.8285 and valued at over $56.76 million, while TCG CROSSOVER MANAGEMENT, LLC holds 6.4535 of the shares totaling 3.19 million with a market value of $37.27 million.
Mineralys Therapeutics Inc (MLYS) Insider Activity
The most recent transaction is an insider purchase by Samsara BioCapital GP, LLC, the company’s 10% Owner. SEC filings show that Samsara BioCapital GP, LLC bought 600,000 shares of the company’s common stock on Mar 13 ’25 at a price of $13.50 per share for a total of $8.1 million. Following the purchase, the insider now owns 5.67 million shares.
Mineralys Therapeutics Inc disclosed in a document filed with the SEC on Mar 13 ’25 that AKKARAJU SRINIVAS (Director) bought a total of 600,000 shares of the company’s common stock. The trade occurred on Mar 13 ’25 and was made at $13.50 per share for $8.1 million. Following the transaction, the insider now directly holds 5.67 million shares of the MLYS stock.
Still, SEC filings show that on Mar 13 ’25, RA CAPITAL MANAGEMENT, L.P. (Director) acquired 1,296,296 shares at an average price of $13.50 for $17.5 million. The insider now directly holds 4,280,051 shares of Mineralys Therapeutics Inc (MLYS).
